What the FDA labels say about taking them together
Bedaquiline and rifapentine
Bedaquiline's FDA label of October 17, 2025 names rifapentine in its warnings and precautions section; the rifapentine label PlainMeds reads does not name bedaquiline. The bedaquiline label: “Avoid coadministration of SIRTURO with moderate or strong CYP3A4 inducers, such as efavirenz and rifamycins.”
Check it at the source: the bedaquiline FDA label on DailyMed (effective October 17, 2025, Janssen Products, LP); the rifapentine FDA label on DailyMed (effective February 6, 2026, sanofi-aventis U.S. LLC).
What does the bedaquiline label say about rifapentine?
Bedaquiline label, warnings and precautionsAvoid coadministration of SIRTURO with moderate or strong CYP3A4 inducers, such as efavirenz and rifamycins (i.e., rifampin, rifapentine and rifabutin) [see Drug Interactions (7.1) ].
Source: FDA drug label (SIRTURO), Janssen Products, LP, effective October 17, 2025 (SPL set 1534c9ae-4948-4cf4-9f66-222a99db6d0e), via openFDA; the full label on DailyMed
What does the rifapentine label say about bedaquiline?
Rifapentine's label (effective February 6, 2026) does not name bedaquiline in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Priftin), sanofi-aventis U.S. LLC, effective February 6, 2026 (SPL set 3a64fb70-b85e-43d9-8bcd-7e893f568ae1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bedaquiline | Rifapentine | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $4.83 per tablet 150 mg tablet |
| Shortage now | No current entry | Resolved |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once